重度抑郁症与肠道微生物群 - 关联而非因果关系。范围综述。

Major Depressive Disorder and gut microbiota - Association not causation. A scoping review.

机构信息

Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, Broniewskiego 24 Street, 71-460 Szczecin, Poland.

Department of Psychiatry, Pomeranian Medical University in Szczecin, Broniewskiego 26, 71-460 Szczecin, Poland.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110111. doi: 10.1016/j.pnpbp.2020.110111. Epub 2020 Sep 23.

Abstract

One very promising hypothesis of Major Depressive Disorder (MDD) pathogenesis is the gut-brain axis (GBA) dysfunction, which can lead to subclinical inflammation, hypothalamic-pituitary (HPA) axis dysregulation, and altered neural, metabolic and endocrine pathways. One of the most important parts of GBA is gut microbiota, which was shown to regulate different functions in the central nervous system (CNS). The purpose of this scoping review was to present the current state of research on the relationship between MDD and gut microbiota and extract causal relationships. Further, we presented the relationship between the use of probiotics and antidepressants, and the microbiota changes. We evaluated the data from 27 studies aimed to investigate microbial fingerprints associated with depression phenotype. We abstracted data from 16 and 11 observational and clinical studies, respectively; the latter was divided into trials evaluating the effects of psychiatric treatment (n = 3) and probiotic intervention (n = 9) on the microbiome composition and function. In total, the data of 1187 individuals from observational studies were assessed. In clinical studies, there were 490 individuals analysed. In probiotic studies, 220 and 218 patients with MDD received the intervention and non-active study comparator, respectively. It was concluded that in MDD, the microbiota is altered. Although the mechanism of this relationship is unknown, we hypothesise that the taxonomic changes observed in patients with MDD are associated with bacterial proinflammatory activity, reduced Schort Chain Fatty Acids (SCFAs) production, impaired intestinal barrier integrity and neurotransmitter production, impaired carbohydrates, tryptophane and glutamate metabolic pathways. However, only in few publications this effect was confirmed by metagenomic, metabolomic analysis, or by assessment of immunological parameters or intestinal permeability markers. Future research requires standardisation process starting from patient selection, material collection, DNA sequencing, and bioinformatic analysis. We did not observe whether antidepressive medications influence on gut microbiota, but the use of psychobiotics in patients with MDD has great prospects; however, this procedure requires also standardisation and thorough mechanistic research. The microbiota should be treated as an environmental element, which considers the aetiopathogenesis of the disease and provides new possibilities for monitoring and treating patients with MDD.

摘要

重度抑郁症(MDD)发病机制的一个非常有前景的假设是肠道-大脑轴(GBA)功能障碍,这可能导致亚临床炎症、下丘脑-垂体(HPA)轴失调以及改变神经、代谢和内分泌途径。GBA 的最重要部分之一是肠道微生物群,它被证明可以调节中枢神经系统(CNS)的不同功能。本综述的目的是介绍 MDD 与肠道微生物群之间关系的研究现状,并提取因果关系。此外,我们还介绍了益生菌和抗抑郁药的使用与微生物群变化之间的关系。我们评估了 27 项旨在研究与抑郁表型相关的微生物指纹的研究的数据。我们分别从 16 项和 11 项观察性和临床研究中提取数据;后者分为评估精神科治疗(n=3)和益生菌干预(n=9)对微生物组组成和功能影响的试验。总共评估了来自观察性研究的 1187 名个体的数据。在临床研究中,有 490 名个体被分析。在益生菌研究中,1187 名 MDD 患者分别接受了干预和非活性对照研究。结论是,在 MDD 中,微生物群发生了改变。尽管这种关系的机制尚不清楚,但我们假设在 MDD 患者中观察到的分类变化与细菌促炎活性、短链脂肪酸(SCFAs)产生减少、肠道屏障完整性和神经递质产生受损、碳水化合物、色氨酸和谷氨酸代谢途径受损有关。然而,只有在少数出版物中,通过宏基因组学、代谢组学分析,或通过评估免疫参数或肠道通透性标志物,证实了这种影响。未来的研究需要从患者选择、材料收集、DNA 测序和生物信息学分析开始进行标准化过程。我们没有观察到抗抑郁药是否会影响肠道微生物群,但 MDD 患者使用心理益生菌有很大的前景;然而,这一过程也需要标准化和深入的机制研究。微生物群应被视为一种环境因素,它考虑了疾病的病因发病机制,并为监测和治疗 MDD 患者提供了新的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索